InsidersTradesSigma
Diamyd Medical AB Stock: price and directors' dealings · Finland · FIN-FSA
Track the Diamyd Medical AB stock price and the full insider trade history of the company, a listed issuer based in Finland. Shares are listed on FI FI, under the oversight of FIN-FSA. Operating in the Health Care sector, Diamyd Medical AB has published 6 reports. Market capitalisation: €168.9m. The latest transaction was disclosed on 24 June 2026 (Purchase). Among the most active insiders: Anders Essen-Möller. All data is free.
6
Insider Decl.
0
Thresholds
€577,635
6 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Diamyd Medical AB Strong Buy (bullish), based on 1 analysts. Average price target: SEK 1.40.
40Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 24 June 2026
Declarations6 total
100,000 shares@ SEK 1.000.0059% mcap1.6% of flowAktieFI:csv-c0583c028b9c2148656e
Ideal exit: 21 Mar 2027 (T+270)
1,000 shares@ €0.90490.0005% mcap100.0% of flowBTU (betald tecknad unit)FI:A003N869-1
Ideal exit: 30 Jan 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
1,020 shares@ €0.72770.0004% mcap100.0% of flowBTU (betald tecknad unit)FI:A003N791-1
Ideal exit: 24 Jan 2026 (T+270)
327,124 shares@ €0.73150.14% mcap42.9% of flowBTU (betald tecknad unit)FI:A003N796-1
Ideal exit: 25 Jan 2026 (T+270)
435,630 shares@ €0.73150.19% mcap57.1% of flowBTU (betald tecknad unit)FI:A003N795-1
Ideal exit: 25 Jan 2026 (T+270)
12,500 shares@ €0.72770.0055% mcap100.0% of flowBTU (betald tecknad unit)FI:A003N704-1
Ideal exit: 24 Jan 2026 (T+270)
6 of 6 declarations
About Diamyd Medical AB
Diamyd Medical AB is a Swedish biopharmaceutical company focused on developing treatments for type 1 diabetes. The company specializes in innovative therapies based on recombinant proteins.